Search results

1

Cardioncology in Russia: Start-Off and Prospects

100%

Ballyuzek M. F., Mashkova M. V.

OncoReview

|

2014

|

vol. 4

|

issue 2

A49-53

EN

The progress in improving the survival of cancer patients in Russia, as well as throughout the world, means that in the next years it is going to be an increase in the number of disabled people who has achieved remission, or who faces the consequences of high-dose polychemotherapy and/or radiotherapy between courses of cancer treatment. Until recently, the two main socially significant medical problems in Russia, cancer and cardiac, have been rarely united into one. Publications on this topic appeared only in specialized cancer journals and were unknown by a wide range of cardiologists and internists, therefore the involvement of these specialists in the study of theoretical and practical aspects of the management of patients with malignant tumors was limited. Creation of the International Society of Cardioncology (ICOS) contributed to the development of an interest in this interdisciplinary field of modern medicine. However, even today cardiac problems of cancer patients in Russia mostly are limited to the cardiotoxicity studying, but, according to the position of the authors a great attention should be paid to the systemic reactions, including cardiovascular reactions of the organism to the tumor, as well as to the therapeutic issues and cardiac rehabilitation of cancer patients.

2

Safety and efficacy of liposomal doxorubicin in a patient treated for metastatic breast cancer

100%

Borucka J.

OncoReview

|

2015

|

vol. 5

|

issue 4

A151-154

EN

Breast cancer is the most common malignancy among women in Poland and all over the world. Despite the development of modern therapies, cytostatics still play one of the main roles in treatment of this disease. Classic anthracyclines, besides unquestionable efficacy in this disease, have a disadvantageous toxicity profile. Therefore, until now, there has been a limitation in using these drugs in patients with cardiological conditions and in patients who had previously taken anthracyclines. That was the cause for the development of a less toxic form of drug, which is liposomal doxorubicin – being as effective as classic anthracycline it has reduced cardiotoxicity. This article presents the case of a patient with metastatic breast cancer, in whom, after treatment with classic doxorubicin, liposomal form was administered which caused regression of liver metastases. Moreover, during treatment with liposomal doxorubicin, there has been no evidence of heart impairment.

3

Cisplatin-induced cardiotoxicity – two case reports

100%

Sawant S. P., Prakruthi J., Daddi A. D., Ghosh J., Joshi A., Alahari Dhir A.

OncoReview

|

2015

|

vol. 5

|

issue 4

A145-150

EN

Cisplatin has been used for over 40 years in various cancer chemotherapies. Toxicity induced by cisplatin-based therapeutic regimens include gastrointestinal toxicity, myelotoxicity, neurotoxicity, ototoxicity and nephrotoxicity. Cisplatin-based regimens have been associated with a wide range of cardiovascular complications. In this paper, we report 2 cases of cisplatin induced cardiotoxicity. We present cases of 2 young patients who developed acute myocardial infarction during combination chemotherapy with bleomycin, etoposide and cisplatin. The first patient had acute anterior wall ST elevation myocardial infarction and the second one had acute myocardial infarction with peripheral arterial thromboembolism. Cisplatin use can result in cardiovascular events. Clinicians should be very cautious while managing patients on cisplatin-based chemotherapy. Early recognition of cardiotoxicity will allow for timely prevention of permanent cardiac damage.

4

Imaging techniques used to detect oncological treatment complications

100%

Sosnowska-Pasiarska B., Góźdź S.

OncoReview

|

2017

|

vol. 7

|

issue 2

57-63

EN

Oncological drugs are toxic for the cardiovascular system, directly affecting cardiac function and anatomy. Oncological treatment complications may thus take the form of asymptomatic myocardial dysfunction, overt heart failure, exacerbation of the symptoms of ischaemic heart disease, thromboembolic complications, arterial and pulmonary hypertension, pericardial complications, valvular disease and arrhythmia. Presently, we have a number of diagnostic tools at our disposal to detect cardiotoxicity, and the choice of one imaging technique over the others depends on the availability of that particular diagnostic method, and on its ability to provide optimum visualization. The basic method for cardiac assessment in oncological patients is transthoracic echocardiography (TTE). It is a widely available method which enables assessment of cardiac structures and haemodynamics without exposing the patient to an additional dose of ionizing radiation. In the case of poor TTE visualization, a recommended method for the assessment of cardiac function and structures is magnetic resonance. Chest, heart and coronary artery CT is also very useful in the diagnostics of oncological treatment complications. Moreover, cardiotoxicity diagnostics also involves nuclear medicine imaging techniques, including gated radionuclide ventriculography, whose advantage is high repeatability, with the disadvantage being the patient’s exposure to ionizing radiation and limited information on the structure and function of the myocardium. Both ECG-gated single photon emission computed tomography (SPECT) and positron emission tomography (PET) deliver information on the global and regional function of the left ventricle, presence of intraventricular synchrony, and myocardial perfusion. Early detection of subclinical dysfunction of the left ventricular myocardium in patients treated with potentially cardiotoxic drugs is well-grounded and aimed at the prevention of cardiovascular mortality by means of a primary prevention strategy.

5

QUERCETIN ATTENUATES OXIDATIVE STRESS, INFLAMMATION AND CARDIAC DYSFUNCTION IN ACRYLAMIDE- INDUCED CARDIOTOXICITY

100%

Kushwah A. S., KALIA T. S.

Acta Poloniae Pharmaceutica - Drug Research

|

2020

|

vol. 77

|

issue 2

343-352

EN

Acrylamide (ACR) is a foodborne toxic agent, formed in food when processed at high temperature. This study aimed at evaluating the biochemical changes induced by ACR and the effect of Quercetin as a treatment against ACR induced cardiotoxicity in rats. Wistar rats of either sex (n=6) were divided into four groups as follows: normal control, an Acrylamide control group, Quercetin groups (25 and 50 mg/kg). Diagnostics characteristics were assessed daily, at the end of the study (4 weeks) evaluate hemodynamic parameters, the blood sample was collect for estimation of biochemical and rats were decapitated excised hearts, cleaned and weighed. Heart homogenate was used to determine antioxidants and oxidative levels, and histopathological evaluations were carried out to determine changes induced by Acrylamide. As compared control groups, ACR treated rats show altered significantly (P < 0.05) general characteristic and also elevated myocardial damage markers, altered hemodynamic, oxidative stress level, increased expression of inflammatory cytokines and induced histopathological changes. Treatment with Quercetin at 25 mg/kg and 50 mg/kg recouped the above changes significantly (P < 0.05), 50 mg/kg being more prominent. The present study has concluded that Quercetin protects against Acrylamide-induced cardiotoxicity.

6

Cardio-oncology in Ukraine: experience at Strazhesko Institute of Cardiology

100%

Kozhukhov S., Dovganych N., Smolanka I., Lyhyrda O.

OncoReview

|

2018

|

vol. 8

|

issue 3

65-69

EN

Anticancer therapies have extended the lives of patients with cancer, but for some, this benefit is tempered by cardiovascular complications. Their number is increasing as a result of an improvement in the early diagnosis of cardiotoxicity caused by chemo- and radiotherapy. Therefore prevention, detection, monitoring, and treatment of cancer patients at risk of cardiotoxicity with or without concomitant CV diseases are very important. Cardio-oncology is a new direction in Ukraine for improving clinical outcomes of cancer patients. This review aims to provide an overview of the rationale for setting up a Cardio-Oncology Unit and reflects our own experience establishing this service.

7

Tyrosine kinase inhibitors – should we worry about cardiovascular complications?

100%

Styczkiewicz K., Sawka D., Styczkiewicz M.

OncoReview

|

2017

|

vol. 7

|

issue 2

70-77

EN

Small-molecular tyrosine kinase inhibitors constitute an effective therapeutic option in patients with hematologic malignancies and solid tumours. On the other hand, the significance of cardiovascular adverse events associated with their use is often emphasised. The events include arterial hypertension, heart failure, coronary disease/acute coronary syndromes, and long QT syndrome. The paper discusses the underlying mechanisms behind cardiovascular events associated with the treatment that involves tyrosine kinase inhibitors, and presents preventive and therapeutic options available in clinical practice. Awareness of the potential cardiovascular complications, regular follow-up, early diagnosis and initiation of appropriate treatment, combined with close collaboration with cardiology specialists, may enhance the benefits of long-term TKI therapy.

8

Nuclear magnetic resonance spectroscopy reveals metabolic changes in living cardiomyocytes after low doses of ionizing radiation

100%

Gramatyka M., Skorupa A., Sokół M.

Acta Biochimica Polonica

|

2018

|

vol. 65

|

issue 2

309-318

EN

Several lines of evidence indicate that exposure of heart to ionizing radiation increases the risk of cardiotoxicity manifested by heart dysfunction and cardiovascular diseases. It was initially believed that the heart is an organ relatively resistant to radiation. Currently, however, it is suspected that even low doses of radiation (< 2 Gy) may have a negative impact on the cardiovascular system. Cardiotoxicity of ionizing radiation is associated with metabolic changes observed in cardiac cells injured by radiation. In this study, we used human cardiomyocytes as a model system, and studied their metabolic response to radiation using high-resolution magic angle spinning nuclear magnetic resonance techniques (HR-MAS NMR). Human cardiomyocytes cultured in vitro were exposed to ionizing radiation and their survival was assessed by clonogenic assay. Changes in apoptosis intensity and cell cycle distribution after the irradiation were measured as well. NMR spectra of cardiomyocytes were acquired using Bruker Avance 400 MHz spectrometer at a spinning rate of 3200 Hz. Survival of cardiomyocytes after NMR experiments was assessed by the Trypan blue exclusion assay. Exposure of cardiomyocytes to small doses of ionizing radiation had no effect on cell proliferation potential and intensity of cell death. However, analysis of metabolic profiles revealed changes in lipids, threonine, glycine, glycerophosphocholine, choline, valine, isoleucine, glutamate, reduced glutathione and taurine metabolism. The results of this study showed that ionizing radiation affects metabolic profiles of cardiomyocytes even at low doses, which potentially have no effect on cell viability.

9

Cardiac amyloidosis: a hidden cause of cardiovascular complications in oncology practice

100%

Mladosievicova B., Poljak Z., El-Hassoun O., Roziakova L., Carter A.

OncoReview

|

2014

|

vol. 4

|

issue 4

A137-A143

EN

Amyloidosis is rare, but known cause of heart failure, cardiomyopathy, coronary artery disease, disorders of cardiac conduction system and valvular damage. Disease often remains undetected until it reaches an advanced stage. Currently, we distinguish several types of amyloidosis. Cardiac amyloidosis may be caused by cancer, chronic inflammation, genetic factors and by aging related processes. Overproduction of amyloidogenic proteins by tumor cells has a key role in the pathogenesis of immunoglobulin light chain amyloidosis. Cardiovascular complications in patients with amyloidosis can be induced by insoluble deposits of misfolded proteins or by direct toxic effects of amyloidogenic molecules on cardiomyocytes and endothelial cells. In this review we focus mainly on pathophysiological mechanisms of cardiac amyloidosis, classification of cardiac amyloidosis types and their cardiovascular manifestations.

10

Non-pegylated liposomal doxorubicin based on treatment of diffuse large B-cell lymphoma in old patient with increased cardiovascular risk – case report and review of literature

100%

Joks M., Urbaniak M.

OncoReview

|

2018

|

vol. 8

|

issue 4

120-126

EN

The use of anthracyclines in the treatment of patients with diffuse large B-cell lymphoma is crucial, however may be sometimes difficult or even contraindicated due to coexisting cardiovascular diseases. An alternative to conventional anthracyclines seems to be liposomal forms that have been registered in the first line of treatment for women with metastatic breast cancer. Data on their use in patients with non-Hodgkin’s lymphomas indicate high efficacy and acceptable toxicity. We present case report of treatment with immunochemotherapy using non-pegylated liposomal doxorubicin in elderly woman with diffuse large B-cell lymphoma coexisting with ischemic heart disease, hypertension, type 2 diabetes. In addition, we present review of literature and the aspects of the use of drugs off-label.

11

Complete response to pixantrone as a salvage therapy in a relapsed/refractory diffuse large B-cell lymphoma

100%

Pasternak A.

|

EN

Diffuse large B-cell lymphoma (DLBCL) is an aggressive form of non-Hodgkin lymphoma (NHL). It is one of the most common form of the disease. A combination of chemotherapy with anthracycline and a monoclonal antibody targeting CD20 is used as a I line therapy. About two out of three people with DLBCL achieve and maintain complete remission after this treatment. In case of relapse or refractory disease a salvage high‑dose chemotherapy followed by autologous stem cell transplantation (HD-ASCT) is the standard of care. Patientrs who relapse after HD-ASCT have a very poor prognosis. Pixantrone is a new anthracycline derivative registered to treat relapsed/refractory DLBCL in adult patients. It is a cytostatic agent with a reduced cardiotoxicity comparing to classic anthracyclines. Herein, we report two cases of relapsed/refractory DLBCL treated with pixantrone as a salvage therapy. The first case concernes a 58-year-old female patient with a diagnose of DLBCL, who relapsed after four prior lines of therapy (R-CHOP, ICE, HD-Mtx, CSN radiation) and achieved complete remission after pixantrone therapy, but died of acute myeloid leukemia 3 months after the end of treatment. Second case is a story of a 75-year-old female patient treated with two prior lines of treatment (R-CHOP, R-IVE), who achieved complete remission after a III line of therapy with pixantrone. Pixantrone monotherapy proves to be effective in relapsed/refractory DLBCL. This treatment is well tolerated in a group of elderly patients and can be also used in a group of patients with a limited cardiac function.

12

Cardiotoxicity in breast cancer patients after radiotherapy – modern methods of minimizing the dose to the heart and dilemmas of choosing critical cardiac structures for monitoring dose distribution

100%

Pudełek K., Pudełek J., Nawrocki S.

|

EN

Radiotherapy in breast cancer patients is an important component of multidisciplinary treatment. It reduces the risk of local recurrence and mortality from breast cancer. However, it can lead to secondary effects due to the presence of the heart within the irradiation field. Adjuvant radiation therapy for breast cancer increases the risk of coronary artery disease, myocardial infarction and cardiovascular death. It is important to determine the optimal treatment to minimize cardiotoxicity. Modern radiotherapy techniques may reduce radiation-induced cardiac toxicity, but it is necessary to determine the most sensitive structures within the heart, tolerance doses, and methods for early detection and monitoring of adverse effects.

13

Pixantrone – anticancer drug in the monotherapy of aggressive lymphomas

100%

Hałka J.

OncoReview

|

2020

|

vol. 10

|

issue 2

48-51

EN

Pixantrone is a first drug aza-anthracenedione approved as monotherapy of relapsed or refractory aggressive lymphomas. This drug has the unique chemical structure and mode of action properties distinguishing it from anthracyclines and anthracenediones. Pixantrone is one of the treatment option for heavily pretreated patients which to receive their living with doxorubicin and the further application from anthracyclines potentially can lead anthracycline-induced congestive heart failure. The benefit of pixantrone treatment has not been established in patients when used as V line or greater chemotherapy in patients who are refractory to last therapy. In general, pixantrone seems to be safe and manageable. In various trials, there were no unexpected side effects reported and no trials were closed prematurely because of side effects. In an evaluation of 12 clinical trials with pixantrone, the most common side effect (all grades) was hematological toxicity, mainly neutropenia (50% of patients; grade third/fourth: 41%), leukopenia (25%), anemia (31%), and thrombocytopenia (21%). Hematological toxicity was the main reason for a delayed start of subsequent cycles or for omitting the day-15 dose of pixantrone. In the outpatient setting, it is worth considering the use of hematopoietic growth factors. Other side effects included asthenia (23%), pyrexia (23%), and nausea, most patients experienced reversible skin discoloration

14

Efficacy and safety of liposomal doxorubicin in a patient treated for metastatic breast cancer

100%

Streb J., Słowik A.

OncoReview

|

2015

|

vol. 5

|

issue 2

A67-70

EN

Liposomal doxorubicin is a newer form of chemotherapeutic agents that, due to its own special properties, preferably accumulates in cancer tissue. On the other hand, it shows lower affinity to cardiomyocytes and in this way is less cardiotoxic. As a result of that, there is the possibility to use liposomal form of doxorubicin until disease progression or chemotherapy intolerance in palliative setting, without treatment cessation after reaching the maximum cumulative dose of conventional doxorubicin. In this article we describe the case of a female patient diagnosed with breast cancer who was primary treated with adjuvant treatment, including chemotherapy and in whom a disease recurrence occurred after seven years of observation. As a primary palliative treatment the patient received chemotherapy based on liposomal doxorubicin and cyclofosphamide with a very good tolerance. The initial response was partial remission in lungs and in mediastinal lymph nodes. During the whole course of therapy there were no pathological changes in electrocardiogram, no signs and no symptoms of congestive heart failure, and the left ventricular ejection fraction was within normal limits.

15

Liposomal doxorubicin in first line metastatic HER-2-positive breast cancer for prevention the cardiotoxicity

100%

Chmielowska E.

OncoReview

|

2015

|

vol. 5

|

issue 1

A11-A15

EN

We describe a 62 year old female with metastatic HER-2-positive breast cancer, and with independent cardiovascular comorbidities. She was earlier treated with J131 therapy due to thyroid toxicity. She developed grade 2 mitral and tricuspid valvular insufficiency as a result of uncontrolled hypertension. In 2013, the patient was diagnosed with luminal B2 breast cancer with liver and bone metastases, and a large infiltration of the left breast together with the surrounding soft tissue. She was treated with liposomal doxorubicin and cyclophosphamide, with the dose of anthracycline slightly reduced to 50 mg/m2 because of the elevated liver enzymes. She was in complete remission during treatment, without any cardiac or hematologic toxicity. The treatment was prolonged to eight cycles until the liver tests returned to normal. The cumulative dose of liposomal doxorubicin amounted to 400 mg/m2 (with the maximum recommended dose of 600 mg/m2). We decided to administer the liposomal form of doxorubicin, which is less cardiotoxic than conventional doxorubicin, as first-line treatment in order to prevent cardiotoxicity in a patient who is a candidate for another cardiotoxic therapy involving trastuzumab in the future. The patient’s disease progressed 10 months following the completion of first-line therapy. There are no cardiologic contraindications to trastuzumab and there are no signs of liposomal doxorubicin-related cardiotoxicity or deterioration of the valvular insufficiency.

16

Limitations in cardiovascular fitness and rehabilitation of oncologically treated patients

100%

Hojan K.

Medical Rehabilitation

|

2012

|

vol. 16(1)

19-25

PL

Wstęp: Zastosowanie co raz nowszych form terapii w leczeniu onkologicznym poprawia skutecznie przeżycie chorych na nowotwory. Nadal jednak każdy element tej terapii, jakkolwiek bardzo skuteczny, niesie ryzyko powikłań ze strony układu krążenia. Cel: Celem badań było przedstawienie przeglądu badań klinicznych oceniających powikłania w układzie sercowo-naczyniowym wynikające z zastosowania różnych form leczenia onkologicznego oraz rehabilitacji w tej grupie pacjentów. Materiał: W pracy przedstawiono współczesne leczenie nowotworów, które może powodować objawy niepożądane z zakresu układu sercowo-naczyniowego. Wyniki: Leki onkologiczne ze względu na negatywny wpływ na układ sercowo-naczyniowy podzielono na: powodujące utratę masy mięśnia sercowego, wywołujące zaburzenia rytmu i przewodzenia, o działaniu kardiodepresyjnym, powodujące nadciśnienie, niedokrwienie mięśnia sercowego oraz sprzyjające incydentom zakrzepowo-zatorowym. Kardiotoksyczność terapii onkologicznej jest szczególnie wyrażona u pacjentów po leczeniu skojarzonym (z zastosowaniem chemioterapii i radioterapii) lub współistniejącą chorobą serca. Zgodnie z klasyfikacją niewydolności serca kaŜdy pacjent po chemioterapii i/lub radioterapii ma zwiększone ryzyko jej rozwoju, dlatego ważna jest znajomość rodzaju stosowanego leczenia onkologicznego, jego dawek, cykli i czasu od rozpoczęcia lub zakończenia leczenia, aby program usprawniania dla tej grupy pacjentów, oparty o zastosowanie wysiłku fizycznego, był realizowany poprzez właściwą aktywność fizyczną i pod kontrolą lekarza. Wnioski: Korzyść onkologiczna terapii jest dużo wyższa niż potencjalne ryzyko kardiologiczne, ale mając na uwadze dobro pacjenta, konieczna jest optymalna diagnostyka kardiologiczna i prowadzenie rehabilitacji w zależności od określonej wydolności krążenia. U chorych leczonych onkologicznie należy ze szczególną uwagą ocenić wydolność krążeniowo-oddechową przed rozpoczęciem rehabilitacji oraz zaproponowaniem aktywności fizycznej (np. dyscypliny sportowej) w tej grupie pacjentów.

EN

Introduction: Applying increasingly modern forms of cancer treatment contributes to the higher survival of patients with neoplasm. Nevertheless, every single element of such a treatment, no matter how effective, brings some risk of cardiovascular complications.Objective: The study objective was a review of the clinical research analyzing cardiovascular complications resulting from various forms of oncological treatment and the use of rehabilitation in these patients.Material: The study presents contemporary forms of cancer treatment which may cause negative cardiovascular symptoms.Results: Due to their negative influence on the cardiovascular system oncological drugs can be divided into those: causing heart muscle mass loss, arrhythmia, with a cardio depressive effect, hypertension, heart ischemia as well as those enhancing thrombo-embolic disorders. The cardiotoxicity of oncological treatment is very frequent in patients after combination therapy (using chemotherapy or/and radiotherapy) or with coexisting heart disease. According to the heart failure classification every patient after chemotherapy or/and radiotherapy has a higher risk of its development. Thus it is important to know the type of treatment, its dosages, the time from initiation to the treatment completion, so that the rehabilitation program for this group of patients based on exercise is applied through correct medically supervised physical activities.Conclusions: The oncological benefit of therapy is much higher than the possible cardiological risk but, keeping the patient’s wellbeing in mind, an optimal cardiac diagnostic is necessary so as rehabilitation is based on individual cardiac fitness. In patients with cancer, special attention should be paid to the assessment of the cardio-respiratory endurance rates before rehabilitation and the choice of physical activity, sporting discipline made for this group of patients.

17

Ocena kardiotoksyczności u pacjentek z rakiem piersi leczonych trastuzumabem*

100%

Sidło-Stawowy A., Sawicka M., Kubeczko M., Sikoń E., Piszko J., Maruszczyk W., Stando R., Bracik J.

Annales Academiae Medicae Silesiensis

|

2013

|

vol. 67

|

issue 2

123-127

EN

INTRODUCTION Breast cancer is the most frequent malignancy in women in Poland. Overexpression of the HER2 receptor positively correlates with the aggressiveness of the disease. Trastuzumab, a humanized monoclonal antibody against HER2, radically improves the prognosis in such patients. However, its main side effect is cardiotoxicity. The aim of this study is to evaluate the cardiotoxicity in trastuzumab-treated patients. MATERIALS AND METHODS The cases of 19 women treated in the Department of Internal Medicine and Oncologic Chemotherapy Medical University of Silesia in Katowice in the period of 2010–2011 were retrospectively analyzed. RESULTS The median age at the time of diagnosis – 57 years, pathology: invasive ductal carcinoma in 17, invasive lobular carcinoma in 2 patients. Overexpression of HER2 was observed in all the cases. Trastuzumab was administered to 16 of them after previous therapy with antracyclines and/or taxan; the median total antracycline dose was 680 mg. Moreover, 13 patients were subjected to radiotherapy; the median total dose was 50 Gy. In 3 patients, trastuzumab and chemotherapy was used in the management of metastasized disease. The median time between the administration of trastuzumab and anthracyclines was 3 months. The median number of cycles was 10. Before administration of the drug, ECG and echocardiography were performed along with ejection fraction (EF) assessment. Before and after therapy the median EF was 65% and 61%, respectively. The therapy was withheld in 1 patient because of a decrease in EF to 40%. CONCLUSIONS The treatment with trastuzumab was well tolerated. In most patients, we did not observe a significant decrease in EF. However, the cases should be followed up to detect delayed cardiotoxicity.

PL

WSTĘP Rak piersi to najczęstszy nowotwór złośliwy u kobiet w Polsce. W praktyce klinicznej ważne jest określenie ekspresji receptorów, w tym dla naskórkowego czynnika wzrostu typu 2 (HER2) na komórkach nowotworowych. Gdy komórki te wykazują wzmożoną ekspresję HER2, przebieg choroby jest agresywniejszy. Trastuzumab, humanizowane przeciwciało monoklonalne przeciw HER2, znacząco poprawia rokowanie. Jednak terapia taka nie jest pozbawiona działań niepożądanych, w tym kardiotoksyczności. Celem pracy była ocena kardiotoksyczności leczenia trastuzumabem u pacjentek z rakiem piersi. MATERIAŁ I METODY Dokonano retrospektywnej analizy historii chorób 19 kobiet leczonych w Klinice Chorób Wewnętrznych i Chemioterapii Onkologicznej Śląskiego Uniwersytetu Medycznego w Katowicach w latach 2010–2011. WYNIKI Mediana wieku w chwili rozpoznania – 57 lat, typ histologiczny: rak przewodowy naciekający u 17, rak zrazikowy naciekający u 2 pacjentek. Nadekspresję HER2 stwierdzono u wszystkich 19 kobiet, u 16 z nich zastosowano trastuzumab po wcześniejszym leczeniu upełniającym antracyklinami i/lub taksanami – mediana sumarycznej dawki antracyklin 680 mg. U 13 pacjentek dodatkowo przeprowadzono radioterapię – mediana dawki sumarycznej 50 Gy. U 3 pacjentek podano trastuzumab oraz chemioterapię w leczeniu rozsianej choroby nowotworowej. Mediana czasu włączenia trastuzumabu po antracyklinach wyniosła 3 miesiące. Liczba cykli: mediana 10. Przed włączeniem leku wykonano badanie EKG i czynnościowe serca z oceną frakcji wyrzutowej (EF). Mediana EF przed rozpoczęciem leczenia: 65%, po leczeniu: EF 61%. U jednej pacjentki przerwano leczenie z powodu obniżenia EF do 40%. WNIOSKI Leczenie trastuzumabem było dobrze tolerowane. U większości pacjentek nie obserwowano znamiennego obniżenia EF wymagającego odstawienia leku. Badana grupa wymaga jednak badań czynnościowych serca również po odstawienia trastuzumabu w celu wykrycia późnych powikłań kardiotoksycznych.

18

Cardiac endothelial cells isolated from mouse heart - a novel model for radiobiology

88%

Jelonek K., Walaszczyk A., Gabryś D., Pietrowska M., Kanthou C., Widłak P.

Acta Biochimica Polonica

|

2011

|

vol. 58

|

issue 3

397-404

EN

Cardiovascular disease is recognized as an important clinical problem in radiotherapy and radiation protection. However, only few radiobiological models relevant for assessment of cardiotoxic effects of ionizing radiation are available. Here we describe the isolation of mouse primary cardiac endothelial cells, a possible target for cardiotoxic effects of radiation. Cells isolated from hearts of juvenile mice were cultured and irradiated in vitro. In addition, cells isolated from hearts of locally irradiated adult animals (up to 6 days after irradiation) were tested. A dose-dependent formation of histone γH2A.X foci was observed after in vitro irradiation of cultured cells. However, such cells were resistant to radiation-induced apoptosis. Increased levels of actin stress fibres were observed in the cytoplasm of cardiac endothelial cells irradiated in vitro or isolated from irradiated animals. A high dose of 16 Gy did not increase permeability to Dextran in monolayers formed by endothelial cells. Up-regulated expression of Vcam1, Sele and Hsp70i genes was detected after irradiation in vitro and in cells isolated few days after irradiation in vivo. The increased level of actin stress fibres and enhanced expression of stress-response genes in irradiated endothelial cells are potentially involved in cardiotoxic effects of ionizing radiation.

19

Acute coronary syndrome in cancer patients. Part I: pathophysiology, clinical presentation and diagnosis

88%

Piotrowski G.

OncoReview

|

2020

|

vol. 10

|

issue 2

41-47

EN

Coexistence of cardiovascular diseases and cancer is more and more common in everyday practice. This is due to the aging of the population and the fact that most of the classic cardiovascular risk factors also predispose to cancer. During anti-cancer treatment, cardiovascular components may be damaged and eventually lead to acute coronary syndrome. The first part of the review article presents the pathophysiology, clinical presentation and key elements of the diagnostic process of this life-threatening condition in cancer patients.

20

Application of pixantrone in a III line of treatment as a bridge therapy to allotransplantation of stem cells

88%

Kwiatkowska-Pamuła A., Janeczek A., Giebel S.

OncoReview

|

2020

|

vol. 10

|

issue 2

57-61

EN

Diffuse large B-cell lymphomas are the most common group among all lymphomas. Despite the effectiveness of the I line therapy in 10–40% of patients, the possibility of relapse should be taken into account. The anthracycline antibiotics used in the II line therapy carry a high risk of cardiac complications. In patients with refractory or recurrent disease, emergency treatment is used, aiming for the transplantation of hematopoietic cells. If the II line therapy fails, the prognosis is bad. A new chance for patients with refractory or recurrent B-cell lymphoma is pixantrone dimaleate, a drug structurally related to anthracyclines with a significantly lower cardiotoxic potential. The paper presents a case of a 65-year-old patient with relapsing DLBCL lymphoma, after two treatment lines: R-CHOP and R-DHAP, and after autologous transplantation of stem cells, in which the use of pixantrone in the treatment of recurrence allowed to achieve remission and prepare the patient for the allo-HSCT procedure.

Refine search results

Cardioncology in Russia: Start-Off and Prospects

Safety and efficacy of liposomal doxorubicin in a patient treated for metastatic breast cancer

Cisplatin-induced cardiotoxicity – two case reports

Imaging techniques used to detect oncological treatment complications

QUERCETIN ATTENUATES OXIDATIVE STRESS, INFLAMMATION AND CARDIAC DYSFUNCTION IN ACRYLAMIDE- INDUCED CARDIOTOXICITY

Cardio-oncology in Ukraine: experience at Strazhesko Institute of Cardiology

Tyrosine kinase inhibitors – should we worry about cardiovascular complications?

Nuclear magnetic resonance spectroscopy reveals metabolic changes in living cardiomyocytes after low doses of ionizing radiation

Cardiac amyloidosis: a hidden cause of cardiovascular complications in oncology practice

Non-pegylated liposomal doxorubicin based on treatment of diffuse large B-cell lymphoma in old patient with increased cardiovascular risk – case report and review of literature

Complete response to pixantrone as a salvage therapy in a relapsed/refractory diffuse large B-cell lymphoma

Cardiotoxicity in breast cancer patients after radiotherapy – modern methods of minimizing the dose to the heart and dilemmas of choosing critical cardiac structures for monitoring dose distribution

Pixantrone – anticancer drug in the monotherapy of aggressive lymphomas

Efficacy and safety of liposomal doxorubicin in a patient treated for metastatic breast cancer

Liposomal doxorubicin in first line metastatic HER-2-positive breast cancer for prevention the cardiotoxicity

Limitations in cardiovascular fitness and rehabilitation of oncologically treated patients

Ocena kardiotoksyczności u pacjentek z rakiem piersi leczonych trastuzumabem*

Cardiac endothelial cells isolated from mouse heart - a novel model for radiobiology

Acute coronary syndrome in cancer patients. Part I: pathophysiology, clinical presentation and diagnosis

Application of pixantrone in a III line of treatment as a bridge therapy to allotransplantation of stem cells